The University of Texas MD Anderson Cancer Center | Strategic Alliance Partners

Vivek Subbiah, MD, discusses the utility of tivozanib in renal cell carcinoma.

Preetesh Jain, MD, PhD, discusses response and resistance to venetoclax (Venclexta) in relapsed/refractory mantle cell lymphoma (MCL).

Van K. Morris, MD, discusses the role of immunotherapy in metastatic colorectal cancer.

Preetesh Jain, MD, PhD, evaluates mechanisms of resistance to venetoclax in patients with heavily pretreated mantle cell lymphoma and the next phase of this research.

Van K. Morris, MD, discusses the role of immunotherapy in metastatic colorectal cancer.

Preetesh Jain, MD, PhD, evaluated mechanisms of resistance to venetoclax in patients with heavily pretreated mantle cell lymphoma and the next phase of this research.

Michael Wang, MD, discusses research trends in mantle cell lymphoma (MCL).

Rogerio C. Lilenbaum, MD, discusses the rise of immunotherapy in non–small cell lung cancer.

Rogerio C. Lilenbaum, MD, discusses the rise of immunotherapy in non–small cell lung cancer. 

Naval G. Daver, MD, discusses anticipated breakthroughs in acute myeloid leukemia (AML).

Naval G. Daver, MD, discusses anticipated breakthroughs in acute myeloid leukemia (AML).

Prithviraj Bose, MD, discusses novel agents under investigation in myelofibrosis.

Michael Wang, MD, discusses the evolution of treatment in mantle cell lymphoma.

Prithviraj Bose, MD, discusses the role of ruxolitinib in myelofibrosis, the potential advantages of next-generation JAK inhibitors, and other novel agents under exploration.

Michael Wang, MD, discusses the evolution of treatment in mantle cell lymphoma.

Prithviraj Bose, MD, discusses the current role of ruxolitinib in myelofibrosis, the potential advantages of next-generation JAK inhibitors, and the novel agents that are being explored as single agents and in combination with ruxolitinib. 

Jiaxin (Jason) Niu, MD, PhD, discusses combining immunotherapy with VEGF Inhibitors in extensive-stage small cell lung cancer.

Shannon N. Westin, MD, MPH, discusses novel targets in endometrial cancer.

Brandon G. Smaglo, MD, FACP, discusses novel therapies in advanced gastric cancer.

David S. Hong, MD, discusses the results of these analyses with larotrectinib in patients with NTRK alterations.

Shannon N. Westin, MD, MPH, discusses novel targets in endometrial cancer.

Brandon G. Smaglo, MD, FACP, discusses novel therapies in advanced gastric cancer.

Michael Wang, MD, discusses the results of the phase 2 ZUMA-2 trial in relapsed/refractory mantle cell lymphoma.

Michael J. Overman, MD, professor in the Department of Gastrointestinal Medical Oncology of the Division of Cancer Medicine and committee vice chair at The University of Texas MD Anderson Cancer Center, discusses ongoing research with immunotherapy in microsatellite stable (MSS) colorectal cancer (CRC).

Shannon N. Westin, MD, MPH, FACOG, discusses future directions in endometrial cancer.

Michael Wang, MD, discusses unique properties of the investigational CAR T-cell therapy KTE-X19 in relapsed/refractory mantle cell lymphoma.

Nizar M. Tannir, MD, FACP, discusses the 42-month follow-up results from the CheckMate-214 trial in advanced renal cell carcinoma and provides perspective on other approved combinations in the frontline setting.

In our exclusive interview, Dr. Hortobagyi shares his journey in the development of anthracyclines and taxanes, biphosphonates, and gene therapies in breast cancer, some of the challenges he has encountered along the way, and what he hopes to tackle in the rest of his monumental career.

Hoping to minimize the off-target effects associated with radiation in patients with oropharyngeal cancer, investigators are testing the hypothesis that intensitymodulated proton therapy can deliver doses as effectively as the current standard of care with less damage to surrounding tissue.

Ryan W. Huey, MD, assistant professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the landscape of hepatocellular carcinoma (HCC).